142 related articles for article (PubMed ID: 28024798)
1. Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system x
Bentea E; Van Liefferinge J; Verbruggen L; Martens K; Kobayashi S; Deneyer L; Demuyser T; Albertini G; Maes K; Sato H; Smolders I; Lewerenz J; Massie A
Exp Neurol; 2017 Apr; 290():15-28. PubMed ID: 28024798
[TBL] [Abstract][Full Text] [Related]
2. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
Li C; Biswas S; Li X; Dutta AK; Le W
J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
[TBL] [Abstract][Full Text] [Related]
3. Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.
Harrison IF; Anis HK; Dexter DT
Neurosci Lett; 2016 Feb; 614():16-23. PubMed ID: 26742637
[TBL] [Abstract][Full Text] [Related]
4. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.
Savolainen MH; Albert K; Airavaara M; Myöhänen TT
Exp Brain Res; 2017 Jul; 235(7):2189-2202. PubMed ID: 28439627
[TBL] [Abstract][Full Text] [Related]
5. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
Arawaka S; Fukushima S; Sato H; Sasaki A; Koga K; Koyama S; Kato T
PLoS One; 2014; 9(2):e89076. PubMed ID: 24586512
[TBL] [Abstract][Full Text] [Related]
6. MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT.
Bentea E; Sconce MD; Churchill MJ; Van Liefferinge J; Sato H; Meshul CK; Massie A
Neurosci Lett; 2015 Apr; 593():1-6. PubMed ID: 25766755
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
Xie W; Li X; Li C; Zhu W; Jankovic J; Le W
J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice.
Miyazaki I; Murakami S; Torigoe N; Kitamura Y; Asanuma M
J Neurochem; 2016 Jan; 136(1):194-204. PubMed ID: 26485447
[TBL] [Abstract][Full Text] [Related]
9. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Sano H; Murata M; Nambu A
J Neurochem; 2015 Jul; 134(2):371-81. PubMed ID: 25857446
[TBL] [Abstract][Full Text] [Related]
10. Systemic LPS-induced neuroinflammation increases the susceptibility for proteasome inhibition-induced degeneration of the nigrostriatal pathway.
Deneyer L; Albertini G; Bentea E; Massie A
Parkinsonism Relat Disord; 2019 Nov; 68():26-32. PubMed ID: 31621614
[TBL] [Abstract][Full Text] [Related]
11. The Protective Effect of Repeated 1MeTIQ Administration on the Lactacystin-Induced Impairment of Dopamine Release and Decline in TH Level in the Rat Brain.
Wąsik A; Romańska I; Zelek-Molik A; Nalepa I; Antkiewicz-Michaluk L
Neurotox Res; 2018 Oct; 34(3):706-716. PubMed ID: 30129004
[TBL] [Abstract][Full Text] [Related]
12. G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
Xiao Q; Yang S; Le W
J Neural Transm (Vienna); 2015 Dec; 122(12):1645-57. PubMed ID: 26253900
[TBL] [Abstract][Full Text] [Related]
13. Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats.
Lorenc-Koci E; Lenda T; Antkiewicz-Michaluk L; Wardas J; Domin H; Smiałowska M; Konieczny J
Neurochem Int; 2011 Jun; 58(7):839-49. PubMed ID: 21419185
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of zonisamide target astrocyte.
Asanuma M; Miyazaki I; Diaz-Corrales FJ; Kimoto N; Kikkawa Y; Takeshima M; Miyoshi K; Murata M
Ann Neurol; 2010 Feb; 67(2):239-49. PubMed ID: 20225289
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
16. Caloric Restriction Protects against Lactacystin-Induced Degeneration of Dopamine Neurons Independent of the Ghrelin Receptor.
Coppens J; Bentea E; Bayliss JA; Demuyser T; Walrave L; Albertini G; Van Liefferinge J; Deneyer L; Aourz N; Van Eeckhaut A; Portelli J; Andrews ZB; Massie A; De Bundel D; Smolders I
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273852
[TBL] [Abstract][Full Text] [Related]
17. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
Stayte S; Rentsch P; Li KM; Vissel B
PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
[TBL] [Abstract][Full Text] [Related]
18. Intrastriatal transplantation of GDNF-engineered BMSCs and its neuroprotection in lactacystin-induced Parkinsonian rat model.
Wu J; Yu W; Chen Y; Su Y; Ding Z; Ren H; Jiang Y; Wang J
Neurochem Res; 2010 Mar; 35(3):495-502. PubMed ID: 19894114
[TBL] [Abstract][Full Text] [Related]
19. [Sleep changes during degeneration of neurons in the substantia nigra induced by inhibitor of proteasomes lactacystin in rats].
Pastukhov IuF; Chesnokova AIu; Iakimchuk AA; Ekimova IV; Romanova IV; Khudik KA
Ross Fiziol Zh Im I M Sechenova; 2010 Dec; 96(12):1190-202. PubMed ID: 21473106
[TBL] [Abstract][Full Text] [Related]
20. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
